Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH093897, MH086828, MH107615)
U.S. Department of Veterans Affairs (Merit 1I01BX004062)
Received: 20 December 2019
Accepted: 14 July 2022
First Online: 30 August 2022
: C.A.Z. is a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. P.Z., J.N.H., R.M., C.A.Z. and T.D.G. are co-inventors in patents or patent applications related to the pharmacology and use of (<i>2R,6R</i>)-HNK in the treatment of depression, anxiety, anhedonia, suicidal ideation and post-traumatic stress disorders. R.M. and C.A.Z. have assigned their patent rights to the US government but will share a percentage of any royalties that may be received by the government. P.Z., J.N.H. and T.D.G. have assigned their patent rights to the University of Maryland Baltimore but will share a percentage of any royalties that may be received by the University of Maryland Baltimore. T.D.G. has received research funding from Allergan and Roche Pharmaceuticals and has served as a consultant for FSV7 LLC, during the preceding 3 yr. All other authors declare no competing interests.